A practical reference on heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-24. Anything still debated is marked as such rather than presented as settled.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
If on the other hand, the probe sequence encounters a target sequence with as little as one non-complementary nucleotide, the molecular beacon will preferentially stay in its natural hairpin state and no fluorescence will be observed, as the fluorophore remains quenched. The unique design of these molecular beacons allows for a simple diagnostic assay to identify SNPs at a given location. If a molecular beacon is designed to match a wild-type allele and another to match a mutant of the allele, the two can be used to identify the genotype of an individual. If only the first probe's fluorophore wavelength is detected during the assay then the individual is homozygous to the wild type. If only the second probe's wavelength is detected then the individual is homozygous to the mutant allele. Finally, if both wavelengths are detected, then both molecular beacons must be hybridizing to their complements and thus the individual must contain both alleles and be heterozygous.
In January 2026, the Moore administration reached annual pay agreements with six state employee unions, but failed to reach an agreement with AFSCME Maryland Council 3, the state's largest union of state government workers, by the December 31 deadline. Despite this, a pay increase for AFSCME-represented workers equivalent to agreements reached with several smaller unions that average 2% was included in Moore's fiscal year 2027 budget proposal.
The university consolidated its physicians' practice plans and transferred them, along with the university's hospital management functions, to UPMC, with UPMC providing ongoing financial support to the university and its academic missions in return. The result was a mutually exclusive partnership formalized by a series of interrelated agreements and mutual executive oversights, which shares numerous board members. This created a decision-making model in which UPMC oversees clinical activity, while the University of Pittsburgh guards academic priorities, particularly faculty-based research. Expansion of UPMC continued in 2001 as Children's Hospital of Pittsburgh began merging with UPMC. Since then, UPMC merged with Mercy Hospital in 2008; opened new Children's Hospital facilities in 2009; integrated Hamot Medical Center in Erie, Pennsylvania, in 2011, Altoona Regional Health System in Altoona, Pennsylvania, in 2013, and Jameson Health System in New Castle, Pennsylvania, in 2016; along with continued expansion of overseas operations and for-profit business ventures. In October 2016, Susquehanna Health, a four-hospital system in north central Pennsylvania, became the first domestic hospital outside Western Pennsylvania to join the UPMC system. UPMC Susquehanna merged with two additional community hospitals in October 2017. In December 2016, WCA Hospital of Jamestown, New York, became the first domestic hospital outside of Pennsylvania in the UPMC system.
Sources: en.wikipedia.org
=== Synthesis === A variety of synthetic routes to β-hydroxy β-methylbutyric acid have been developed. The first reported chemical syntheses approached HMB by oxidation of alkene, vicinal diol, and alcohol precursors:
Theodoric made him quaestor sacri palatii (quaestor of the sacred palace, the senior legal authority) in 507, governor of Lucania and Bruttium, consul in 514 and magister officiorum (master of offices, one of the most senior administrative officials) in 523. He was praetorian prefect (chief minister) under the successors of Theodoric: under Athalaric (Theodoric's grandson, reigned 526–34) in 533 and, between 535 and 537, under Theodahad (Theodoric's nephew, reigned 534–36) and Witiges (Theodoric's grandson-in-law, reigned, 536–40). The major works of Cassiodorus, besides the Bibles, were the Historia Gothorum, a history of the Goths, the Variae and account of his administrative career and the Institutiones divinarum et saecularium litterarum, an introduction to the study of the sacred scriptures and the liberal arts which was influential in the Middle Ages. Byzantine (Eastern Roman) Emperor Justinian I, retook Italy from the Ostrogoths between 535 and 556. He soon lost much of Italy to the Lombards between 568 and 590, but retained the south until 1059–1071, where they thrived and where the Greek language was the official and vernacular language. In Calabria towns such as Stilo and Rossano and San Demetrio Corone achieved great religious status. From the 7th century many monasteries were built in the Amendolea and Stilaro Valleys. Stilo was the destination of hermits and Basilian monks. Many Byzantine churches survive in the region.
In the 1826 General Convention of Friendship, Commerce and Navigation with the king of Denmark, the United States recognised Greenland as a northern possession of the king, and accepted the trade restrictions that Denmark imposed there. In the Treaty of the Danish West Indies, signed in 1916, the US government explicitly recognised Danish sovereignty over all of Greenland. In the 1941 US–Danish agreement, the American Government "reiterate[d] its recognition of and respect for the sovereignty of the Kingdom of Denmark over Greenland". During World War II, the United States defended Greenland at the request of Danish and Greenlandic officials acting without approval from the central government of Denmark, while it was under Nazi occupation. In the 1951 Greenland Defense Agreement, the United States again recognised the sovereignty of the Kingdom of Denmark over all of Greenland. In the 2004 amendment to the Greenland Defense Agreement, the United States recognised Greenland as "an equal part of the Kingdom of Denmark under the Constitution [with] a wide ranging Greenland Home Rule".
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.